

February 18, 2011



## **DelMar Pharma Invited to Present at Leading Life Sciences Conference**

February 18, 2011 - Vancouver, British Columbia - Del Mar Pharmaceuticals is proud to announce that it has been invited to present at the **11th Annual Life Science Innovation Northwest Conference** – the Pacific Northwest’s premier life sciences conference, on March 2-3, 2011 at the Washington State Convention Center in Seattle, Washington.

The conference is sponsored by The Washington Biotechnology & Biomedical Association (WBBA), in partnership with Burrill & Company.

Mr Jeffrey Bacha, Del Mar Pharmaceuticals’ President & CEO will present an overview of the company’s drug development programs to an audience of industry leaders and life science investors.

### **About Del Mar Pharma**

Del Mar Pharmaceuticals is focused on the development and commercialization of proven cancer therapies in high-impact orphan drug indications. The Company’s lead product, VAL-083, VAL-083 benefits from an extensive clinical and pre-clinical research history via studies sponsored by the National Cancer Institute in the United States. Previously published clinical data demonstrate efficacy of chemotherapy with VAL-083 in the treatment GBM and other tumor types.